This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Treatment

Authoring team

Treatment is with:

  • administration of the appropriate factor
  • application of a removable splint
  • starting gentle passive exercise within 48 hours of the bleed

The joint is not aspirated because of the risk of infection.*

Special treatment considerations are required for hemophiliacs presenting with acute hemarthrosis. Coagulation factor replacement should be administered promptly at the first sign of joint bleeding—including the prodromal phase of stiffness or tingling before pain and swelling—ideally within 2 hours of bleed identification. For bleeding into the hip, target joints, or trauma-associated hemarthrosis, higher factor activity levels of 80% to 100% are recommended. (1)

*Arthrocentesis is generally unnecessary when diagnosing joint bleeding in patients with known haemophilia. If required to rule out septic arthritis or relieve pressure from accumulated blood, it should only be performed after factor replacement has raised specific factor levels. (2)

Reference

  1. Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020 Aug;26 Suppl 6:1-158.
  2. De la Corte-Rodriguez H et al. Accelerating recovery from acute hemarthrosis in patients with hemophilia: the role of joint aspiration. Blood Coagul Fibrinolysis. 2019 Apr;30(3):111-119

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2026 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.